Thus, the in vitro examination highlighted the advantages of the complex anti-HCC drug candidate: high precision, optimal IC50, partly due to HA2-dependent evacuation from endosomal vesicles, and notably, the cytotoxicity attributed to the apoptotic properties of tBid [200]. Here, BID is linked to hepatocellular carcinoma.